0

Infectious Disease Treatment Market in China 2016-2020

  • Published: May 2016
  • Pages: 125
  • SKU: IRTNTR9389
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This market research report presents a comprehensive analysis of the infectious disease treatment market in China by application (antibacterial drugs, antiviral drugs, antifungal drugs, and antiparasitic drugs). The leading vendors identified in this market are F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson & Johnson, Merck, and Pfizer.

Outlook of the infectious disease treatment market in China

According to the market research analysts at Technavio, the infectious disease treatment market in China is anticipated to grow steadily at a CAGR of more than 5% over the forecast period. With the increasing use of combination therapies, the infectious disease treatment market is anticipated to have a positive outlook in the coming years. Physicians are increasingly prescribing drugs that are a combination of anti-infective and corticosteroids. While anti-infectives help reduce the infection, the corticosteroids assist in reducing inflammation of the eye which is caused because of the infection. This helps in proving better efficacy as infections are always associated with inflammation of the conjunctival and corneal tissue, resulting in increased irritation. For instance, some common drugs used are Neo-Poly-Dex eye drops by Bausch & Lomb and Maxitrol by Alcon, which contain polymyxin B sulfates and neomycin and dexamethasone.

One of the significant trends spurring the growth of this market is the emergence of interferon-free therapies in the treatment of infectious diseases. At present, hepatitis C treatment relies on the administration of interferon-based therapies in combination with ribavirin. This treatment is associated with several adverse effects such as anemia and leukopenia. Therefore, researchers and vendors are focusing on developing DAAs with minimal side-effects compared to current treatment methods. Moreover, these therapies are intended to be all-oral regimens and once approved; they are anticipated to have a positive effect on the market. The launch of IFN-free therapies is expected to increase significantly the market sales of hepatitis drugs, which will bolster the growth of the infectious disease treatment market in China over the next four years.

Segmentation by application and analysis of the infectious disease treatment market

  • Antibacterial drugs
  • Antiviral drugs
  • Antifungal drugs
  • Antiparasitic drugs

During 2015, the antibacterial drugs segment dominated the market and accounted for a market share of more than 64% in terms of revenue. Tese drugs treat bacterial infections and are also used as bacterial chemotherapeutic agents in the treatment of cancer. The various classes of antibacterial drugs used to treat diseases are beta-lactams, macrolides, aminoglycosides, quinolones, phenicols, tetracyclines, folate antagonists, and other miscellaneous agents. However, the market share for this segment is anticipated to decline by 2020.

Competitive landscape and key vendors

The infectious disease treatment market in China is highly competitive owing to the presence of several well-established small and large providers. The market has tremendous growth opportunities which are resulting in a lot of new players exploring the market. Vendors are also likely to engage in strategic alliances to market and manufacture drugs.

 Key vendors in this market are -

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GSK
  • Johnson & Johnson
  • Merck
  • Pfizer

Other prominent vendors analyzed in this report are Achaogen, Actelion, Adenovir Pharma, AstraZeneca, Bayer, Biocryst, Celsus Therapeutics, Cempra, Eleven Biotherapeutics, Exoxemis, Ferrer International, Griffin Discoveries, Hexima, InSite Vision, Insmed Incorporated, KaloBios Pharmaceuticals, Lytix Biopharma, Meiji Seika Pharma, Melinta Therapeutics, Moberg Pharma, NanoViricides, Nektar, NicOx, NovaBay, NovaBiotics, Ocular Therapeutix, Panoptes Pharma, Paratek Pharmaceuticals, Polichem, PTC Therapeutics, RedHill, Shire, Starpharma Holdings Limited, Sun Pharma, Symbiomix, Tetraphase Pharmaceuticals, The Medicines Company, Theravance Biopharma, Topica Pharmaceuticals, Vertex Pharmaceuticals, and Viamet Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the infectious disease treatment market in China?
  • What are the key market trends impacting the growth of the infectious disease treatment market in China?
  • What are the challenges to market growth?
  • Who are the key vendors in infectious disease treatment market in China?
  • What are the market opportunities and threats faced by the vendors in the infectious disease treatment market in China?
  • Trending factors influencing the market shares of China.   
  • What are the key outcomes of the five forces analysis of infectious disease treatment market in China?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

 

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of  the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: China - An overview

  • Social and economic conditions
  • Healthcare reforms
  • Healthcare infrastructure

PART 06: Opportunities for global and local vendors

  • Local vendors
  • Global vendors

PART 07: Pipeline analysis

  • AC-170
  • DEXTENZA
  • Zerbaxa
  • Surotomycin
  • MK-3415A
  • Amikacin Inhale
  • CARBAVANCE
  • Eravacycline
  • Plazomicin
  • Delafloxacin
  • Solithromycin
  • VivaGel
  • Arikayce
  • Cadazolid
  • Ozenoxacin
  • TDT 067
  • MOB-015
  • 1334H
  • Auriclosene
  • EBI-005
  • FST-100
  • VT-1161
  • Luliconazole solution, 10%
  • ME1111
  • NP213
  • HXP124
  • SPL7013
  • OPX-1
  • AzaSite Xtra (ISV-405)
  • GD134
  • PART 08: Market landscape
  • Pharmaceutical market in China
  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation  by application

PART 10: Antibacterial drugs market in China

  • MOA
  • Market size and forecast

PART 11: Antiviral drugs market in China

  • Market size and forecast
  • Market segmentation by disease
  • Hepatitis C drugs market in China
  • Hepatitis B drugs market in China
  • HIV drugs market in China

PART 12: Antifungal drugs market in China

  • Market size and forecast

PART 13: Antiparasitic drugs market in China

PART 14: Market drivers

  • Climatic changes
  • Increased exposure to chemicals and pollutants
  • Use of combination therapies
  • Increased prevalence of infectious diseases
  • Increase in awareness

PART 15: Impact of drivers

PART 16: Market challenges

  • Counterfeit drugs
  • Development of drug-resistant strains
  • Patent expiries and generic penetration
  • Decreased investments in research
  • Increased use of generics and CAMs

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Increase in collaborations and M&A
  • Emergence of IFN-free therapies
  • Increase in injection drug users

PART 19: Vendor landscape

  • Competitive scenario
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GSK
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted
Technavio

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Technavio
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>